Petros Pharmaceuticals, Inc. Other Non-Current Liabilities
Petros Pharmaceuticals, Inc. (PTPI) had Other Non-Current Liabilities of $75.22 thousand as of 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OtherLiabilitiesNoncurrent · last filed 2025-03-31
- 2024-12-31: Other Liabilities, Noncurrent $75.22K.
- 2024-09-30: Other Liabilities, Noncurrent $91.83K.
- 2024-06-30: Other Liabilities, Noncurrent $107.76K.
- 2024-03-31: Other Liabilities, Noncurrent $123.02K.
| Period end | Other Liabilities, Noncurrent |
|---|---|
| 2024-12-31 | $75.22K 10-K · filed 2025-03-31 |
| 2024-09-30 | $91.83K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $107.76K 10-Q · filed 2024-08-14 |
| 2024-03-31 | $123.02K 10-Q · filed 2024-05-15 |
| 2023-12-31 | $137.66K 10-K · filed 2025-03-31 |
| 2023-09-30 | $151.40K 10-Q · filed 2023-11-15 |
| 2023-06-30 | $183.33K 10-Q · filed 2023-08-14 |
| 2023-03-31 | $223.57K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $262.68K 10-K · filed 2024-04-01 |
| 2022-09-30 | $300.15K 10-Q/A · filed 2022-11-15 |
| 2022-06-30 | $336.11K 10-Q · filed 2022-08-12 |
| 2022-03-31 | $371.05K 10-Q · filed 2022-05-16 |
| 2021-12-31 | $405.02K 10-K · filed 2023-03-31 |
| 2021-09-30 | $437.75K 10-Q · filed 2021-11-15 |
| 2020-12-31 | $600.92K 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |